Form 4: Twist Bioscience Executive Dennis Cho Acquires 22,824 Shares Through Restricted Stock Unit Vesting

Dennis Cho, a Senior Vice President at Twist Bioscience, acquired 22,824 shares of common stock through the vesting of restricted stock units.

Summary

• Dennis Cho, a Senior Vice President at Twist Bioscience, acquired 22,824 shares of common stock on December 4, 2024.
• The acquisition was a result of restricted stock units (RSUs) vesting.
• These RSUs vest quarterly, with 1/16th of the total award vesting every three months starting from November 20, 2024, over a 48-month period.
• The price of the shares at the time of acquisition was $0, as they were acquired through vesting of RSUs.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to executive compensation, which is generally viewed positively as it aligns management's interests with shareholders. There are no indications of negative sentiment.

Positives

• The vesting of RSUs indicates a continued commitment by the executive to the company's long-term success.
• The acquisition of shares at $0 cost through vesting is a positive incentive for the executive.

Future Outlook

The executive will continue to receive shares as the remaining RSUs vest over the next 48 months, contingent on continued service.

Industry Context

This is a standard practice for executive compensation in publicly traded companies, using equity-based awards to align management's interests with those of shareholders.

Comparison to Industry Standards

• Equity-based compensation, such as restricted stock units, is a common practice among biotechnology companies like Twist Bioscience.
• Companies such as Illumina, Agilent, and Thermo Fisher Scientific also use similar vesting schedules for their executive compensation packages.
• The 48-month vesting period is a typical timeframe for such awards, designed to incentivize long-term commitment and performance.

Stakeholder Impact

• The vesting of RSUs is a positive signal to shareholders, indicating that management is incentivized to increase the company's value.
• The transaction has no immediate impact on employees, customers, suppliers, or creditors.

Next Steps

• The remaining RSUs will continue to vest quarterly over the next 48 months, subject to the executive's continued service.

Key Dates

Keywords

Twist Bioscience, stock acquisition, restricted stock units, RSU, executive compensation, insider trading, vesting